Page 1793 - Williams Hematology ( PDFDrive )

1768 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1769

391. Baur-Melnyk A, Buhmann S, Durr HR, et al: Role of MRI for the diagnosis and prog- 422. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al: Thalidomide in induction treatment
nosis of multiple myeloma. Eur J Radiol 55:56–63, 2005. increases the very good partial response rate before and after high-dose therapy in pre-
392. Joffe J, Williams MP, Cherryman GR, et al: Magnetic resonance imaging in myeloma. viously untreated multiple myeloma. Haematologica 93:124–127, 2008.
Lancet 1:1162–1163, 1988. 423. de la Rubia J, Blade J, Lahuerta JJ, et al: Effect of chemotherapy with alkylating agents
393. Nosas-Garcia S, Moehler T, Wasser K, et al: Dynamic contrast-enhanced MRI for on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish
assessing the disease activity of multiple myeloma: A comparative study with histology Myeloma Group (GEM) Study. Haematologica 91:621–627, 2006.
and clinical markers. J Magn Reson Imaging 22:154–162, 2005. 424. Kumar S, Dispenzieri A, Lacy MQ, et al: Impact of lenalidomide therapy on stem
394. Bredella MA, Steinbach L, Caputo G, et al: Value of FDG PET in the assessment of cell mobilization and engraftment post-peripheral blood stem cell transplantation in
patients with multiple myeloma. AJR Am J Roentgenol 184:1199–1204, 2005. patients with newly diagnosed myeloma. Leukemia 21:2035–2042, 2007.
395. Zamagni E, Nanni C, Patriarca F, et al: A prospective comparison of 18F-fluorodeox- 425. Mark T, Stern J, Furst JR, et al: Stem cell mobilization with cyclophosphamide over-
yglucose positron emission tomography-computed tomography, magnetic resonance comes the suppressive effect of lenalidomide therapy on stem cell collection in multiple
imaging and whole-body planar radiographs in the assessment of bone disease in newly myeloma. Biol Blood Marrow Transplant 14:795–798, 2008.
diagnosed multiple myeloma. Haematologica 92:50–55, 2007. 426. Mazumder A, Kaufman J, Niesvizky R, et al: Effect of lenalidomide therapy on mobi-
396. Zamagni E, Patriarca F, Nanni C, et al: Prognostic relevance of 18-F FDG PET/CT in lization of peripheral blood stem cells in previously untreated multiple myeloma
newly diagnosed multiple myeloma patients treated with up-front autologous trans- patients. Leukemia 22:1280–1281; author reply 1281–1282, 2008.
plantation. Blood 118:5989–5995, 2011. 427. Popat U, Saliba R, Thandi R, et al: Impairment of filgrastim-induced stem cell mobili-
397. International Myeloma Working G: Criteria for the classification of monoclonal gam- zation after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow
mopathies, multiple myeloma and related disorders: A report of the International Mye- Transplant 15:718–723, 2009.
loma Working Group.. Br J Haematol 121:749, 2003. 428. Paripati H, Stewart AK, Cabou S, et al: Compromised stem cell mobilization following
398. Avet-Loiseau H, Durie BG, Cavo M, et al: Combining fluorescent in situ hybridization induction therapy with lenalidomide in myeloma. Leukemia 22:1282–1284, 2008.
data with ISS staging improves risk assessment in myeloma: An International Myeloma 429. Combination chemotherapy versus melphalan plus prednisone as treatment for multi-
Working Group collaborative project. Leukemia 27:711–717, 2013. ple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trial-
399. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autolo- ists’ Collaborative Group. J Clin Oncol 16:3832–3842, 1998.
gous Bone Marrow Transplant and chemotherapy in multiple myeloma. Intergroupe 430. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy versus melphalan
Francais du Myelome. N Engl J Med 335:91–97, 1996. and prednisolone in the treatment of multiple myeloma: An overview of published tri-
400. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory als. J Clin Oncol 10:334–342, 1992.
multiple myeloma. N Engl J Med 341:1565–1571, 1999. 431. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemo-
401. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for therapy plus thalidomide compared with melphalan and prednisone alone in elderly
relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132, 2007. patients with multiple myeloma: Randomised controlled trial. Lancet 367:825–831,
402. Richardson PG, Siegel D, Baz R, et al: Phase 1 study of pomalidomide MTD, safety, and 2006.
efficacy in patients with refractory multiple myeloma who have received lenalidomide 432. Palumbo A, Rajkumar SV, Dimopoulos MA, et al: Prevention of thalidomide- and
and bortezomib. Blood 121:1961–1967, 2013. lenalidomide-associated thrombosis in myeloma. Leukemia 22:414–423, 2008.
403. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, 433. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treat-
refractory myeloma. N Engl J Med 348:2609–2617, 2003. ment for newly diagnosed myeloma: A report from the GIMEMA—Italian Multiple
404. Siegel DS, Martin T, Wang M, et al: A phase 2 study of single-agent carfilzomib Myeloma Network. J Clin Oncol 25:4459–4465, 2007.
(PX-171–003-A1) in patients with relapsed and refractory multiple myeloma. Blood 434. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly
120:2817–2825, 2012. diagnosed multiple myeloma. N Engl J Med 366:1759–1769, 2012.
405. Vij R, Siegel DS, Jagannath S, et al: An open-label, single-arm, phase 2 study of 435. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and predni-
single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma sone for initial treatment of multiple myeloma. N Engl J Med 359:906–917, 2008.
who have been previously treated with bortezomib. Br J Haematol 158:739–748, 2012. 436. Mateos MV, Richardson PG, Schlag R, et al: Bortezomib plus melphalan and predni-
406. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of sone compared with melphalan and prednisone in previously untreated multiple mye-
younger patients with multiple myeloma. Blood 111:2521–2526, 2008. loma: Updated follow-up and impact of subsequent therapy in the phase III VISTA
407. Pulte D, Gondos A, Brenner H: Improvement in survival of older adults with multiple mye- trial. J Clin Oncol 28:2259–2266, 2010.
loma: Results of an updated period analysis of SEER data. Oncologist 16:1600–1603, 2011. 437. Facon TD, Dispenzieri M, Catalano A, et al: Initial phase 3 results of the FIRST
408. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic (Frontline Investigation of Lenalidomide + Dexamethasone versus Standard Thalid-
stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883, 2003. omide) Trial (MM-020/IFM 0701) in newly diagnosed multiple myeloma (NDMM)
409. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high- patients ineligible for stem cell transplantation. ASH 2013 Annual Meeting Abstract
dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup 2, 2013.
Trial S9321. J Clin Oncol 24:929–936, 2006. 438. Ludwig H, Durie BG, McCarthy P, et al: IMWG consensus on maintenance therapy in
410. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell trans- multiple myeloma. Blood 119:3003–3015, 2012.
plantation for multiple myeloma. N Engl J Med 349:2495–2502, 2003. 439. Kagoya Y, Nannya Y, Kurokawa M: Thalidomide maintenance therapy for patients with
411. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus multiple myeloma: Meta-analysis. Leuk Res 36:1016–1021, 2012.
dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319–4323, 2002. 440. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell
412. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for transplantation for multiple myeloma. N Engl J Med 366:1782–1791, 2012.
previously untreated multiple myeloma. J Clin Oncol 21:16–19, 2003. 441. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplan-
413. Cavo M, Zamagni E, Tosi P, et al: Superiority of thalidomide and dexamethasone over tation for multiple myeloma. N Engl J Med 366:1770–1781, 2012.
vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for 442. Palumbo A, Bringhen S, Kumar SK, et al: Second primary malignancies with lenalido-
autologous transplantation for multiple myeloma. Blood 106:35–39, 2005. mide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data.
414. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexametha- Lancet Oncol 15:333–342, 2014.
sone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly 443. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al: Bortezomib induction and main-
diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol tenance treatment in patients with newly diagnosed multiple myeloma: Results of the
11:29–37, 2010. randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30:2946–2955,
415. Lacy MQ, Gertz MA, Dispenzieri A, et al: Long-term results of response to therapy, 2012.
time to progression, and survival with lenalidomide plus dexamethasone in newly diag- 444. Ladetto M, PaglianoG, Avonto I, et al: Consolidation with bortezomib, thalidomide
nosed myeloma. Mayo Clin Proc 82:1179–1184, 2007. and dexamethasone induces molecular remissions in autografted multiple myeloma
416. Richardson PG, Schlossman R, Mitsiades C, et al: Emerging trends in the clinical use of patients. Blood 110:163a, 2007.
bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 6:84–88, 2005. 445. Mellqvist UH, Gimsing P, Hjertner O, et al: Bortezomib consolidation after autologous
417. Jagannath S, Barlogie B, Berenson JR, et al: Bortezomib in recurrent and/or refractory stem cell transplantation in multiple myeloma: A Nordic Myeloma Study Group ran-
multiple myeloma. Initial clinical experience in patients with impaired renal function. domized phase 3 trial. Blood 121:4647–4654, 2013.
Cancer 103:1195–1200, 2005. 446. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell
418. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexametha- transplantation for multiple myeloma. N Engl J Med 366:1782–1791, 2012.
sone combination therapy in patients with newly diagnosed multiple myeloma. Blood 447. Attal M, Roussel M: Maintenance therapy for myeloma: How much, how long, and at
116:679–686, 2010. what cost? Am Soc Clin Oncol Educ Book 32:515–522, 2012.
419. Kumar S, Flinn I, Richardson PG, et al: Randomized, multicenter, phase 2 study (EVO- 448. Palumbo A, Attal M, Roussel M: Shifts in the therapeutic paradigm for patients newly
LUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and diagnosed with multiple myeloma: Maintenance therapy and overall survival. Clin Can-
lenalidomide in previously untreated multiple myeloma. Blood 119:4375–4382, 2012. cer Res 17:1253–1263, 2011.
420. Roussel M, Facon T, Moreau P, et al: Firstline treatment and maintenance in newly 449. Ludwig H, Sonneveld P: Disease control in patients with relapsed and/or refractory
diagnosed multiple myeloma patients. Recent Results Cancer Res 183:189–206, 2011. multiple myeloma: What is the optimal duration of therapy? Leuk Res 36 Suppl 1:S27–
421. Jakubowiak AJ, Dytfeld D, Griffith KA, et al: A phase 1/2 study of carfilzomib in com- S34, 2012.
bination with lenalidomide and low-dose dexamethasone as a frontline treatment for 450. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib
multiple myeloma. Blood 120:1801–1809, 2012. in relapsed or refractory myeloma. Br J Haematol 127:165–172, 2004.

Kaushansky_chapter 107_p1733-1772.indd 1768 9/21/15 12:35 PM